trimetrexate has been researched along with Anemia in 1 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Witte, RS | 1 |
| Yeap, BY | 1 |
| Trump, DL | 1 |
1 trial available for trimetrexate and Anemia
| Article | Year |
|---|---|
Trimetrexate in advanced hormone-refractory prostate cancer. An ECOG phase II trial.
Topics: Aged; Anemia; Humans; Leukopenia; Male; Middle Aged; Prostatic Neoplasms; Thrombocytopenia; Treatmen | 1994 |